Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Total revenue	$ 2,344	$ 8,127	$ 56,830	$ 8,127
Operating costs and expenses:
Cost of products sold	1,454	0	1,563	0
Research and development	104,305	92,050	328,824	246,873
Selling, general and administrative	46,084	36,016	137,461	108,247
Total operating costs and expenses	151,843	128,066	467,848	355,120
Loss from operations	(149,499)	(119,939)	(411,018)	(346,993)
Other income (expense), net:
Interest income	234	692	951	3,567
Interest expense	(11,067)	(10,929)	(31,644)	(25,693)
Other income (expense), net	(684)	9	7,539	(1,344)
Total other income (expense), net	(11,517)	(10,228)	(23,154)	(23,470)
Net loss	(161,016)	(130,167)	(434,172)	(370,463)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests	5,081	14,308	18,810	41,720
Net loss attributable to common stockholders of BridgeBio	$ (155,935)	$ (115,859)	$ (415,362)	$ (328,743)
Net loss per share, basic and diluted	$ (1.06)	$ (0.98)	$ (2.88)	$ (2.79)
Weighted-average shares used in computing net loss per share, basic and diluted	146,662,756	118,168,063	144,044,360	117,663,038
License Revenue
Revenue:
Total revenue	$ 1,585	$ 8,127	$ 55,084	$ 8,127
Product Sales
Revenue:
Total revenue	$ 759	$ 0	$ 1,746	$ 0